Double-Drug attack on rheumatoid arthritis shows promise in new trial
NCT ID NCT04870203
First seen Jan 06, 2026 · Last updated Jun 19, 2026 · Updated 27 times
Summary
This Phase III trial tests whether combining baricitinib with an anti-TNF drug (adalimumab or etanercept) works better than baricitinib alone for people with rheumatoid arthritis who haven't responded to prior treatments. The study involves 160 adults aged 18-65 with active disease. Researchers will measure how many patients achieve a 50% improvement in symptoms (ACR50) and track side effects over 12 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
AP-HM - service de rhumatologie
Marseille, France
-
AP-HP - Hopital Avicenne - service de rhumatologie
Bobigny, France
-
AP-HP - Hôpital Bichat - service de rhumatologie
Paris, France
-
AP-HP - Hôpital Cochin - service de rhumatologie
Paris, France
-
AP-HP - Hôpital Kremlin-Bicêtre - service de rhumatologie
Le Kremlin-Bicêtre, France
-
AP-HP - Hôpital La Pitié-Salpetrière - service de rhumatologie
Paris, France
-
AP-HP - Hôpital Saint-Antoine - service de rhumatologie
Paris, France
-
CH Emile Roux - service rhumatologie
Le Puy-en-Velay, France
-
CH de Belfort - service de rhumatologie
Belfort, France
-
CH de Dax - service de rhumatologie
Dax, France
-
CH de Niort - service de rhumatologie
Niort, France
-
CH de Pau - service de rhumatologie
Pau, France
-
CH de Reims - service de rhumatologie
Reims, France
-
CH de Saint-Malo - service de rhumatologie
St-Malo, France
-
CH de la Côte Basque - service de rhumatologie
Bayonne, France
-
CH du Mans - service de rhumatologie
Le Mans, France
-
CHD VENDEE - service de rhumatologie
La Roche-sur-Yon, France
-
CHRU de Nancy - service de rhumatologie
Vandœuvre-lès-Nancy, France
-
CHRU de Strasbourg - service de rhumatologie
Strasbourg, France
-
CHRU du Tours - service de rhumtologie
Tours, France
-
CHU de Bordeaux - service de rhumatologie
Bordeaux, France
-
CHU de Brest - Service de rhumatologie
Brest, France
-
CHU de Clermont-Ferrand - service de rhumatologie
Clermont-Ferrand, France
-
CHU de Montpellier - service de rhumatologie
Montpellier, France
-
CHU de Nice - service de rhumatologie
Nice, France
-
CHU de Nîmes - service de rhumatologie
Nîmes, France
-
CHU de Saint-Etienne- service de rhumatologie
Saint-Etienne, France
-
CHU de Toulouse - service de rhumatologie
Toulouse, France
-
Clinique de l'Infirmerie - service de rhumatologie
Caluire-et-Cuire, France
-
Groupement des Hôpitaux de l'Institut Catholique de Lille - service de rhumatologie
Lomme, France
-
Hopital NOVO - service de rhumatologie
Pontoise, France
-
Hospices Civils de Lyon - service de rhumatologie
Pierre-Bénite, France
-
Hôpital Saint-Joseph - service de rhumatologie
Marseille, France
-
Nouvel Hôpital Orléans La Source - service de rhumatologie
Orléans, France
-
Polyclinique de Limoges - service de rhumatologie
Limoges, France
-
service de Rhumatologie - CH Princesse Grace
Monaco, Monaco
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
baricitinib and anti-TNF drugs (adalimumab or etanercept)
What this could lead to
If successful, this combination could offer a more effective treatment option for people with rheumatoid arthritis who haven't responded well to other therapies.
What could go wrong
This is a relatively small Phase III trial (160 participants). Combining these drugs may increase the risk of serious side effects, and the benefit may be modest.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.